Announcements Trials
Browse Landscape

Phase

Phase 2 5

Status

Unknown 2Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 3NIH 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 170Head & Neck 18Thoracic 15Tumor-Agnostic 8Genitourinary 7Breast 7Other solid neoplasm 6Gynecologic 5CNS 3Sarcoma 2Myeloid 1Endocrine 1

Conditions

Ovarian Neoplasms 4Fallopian Tube Neoplasms 2Uterine Cervical Neoplasms 1Recurrence 1Neoplasm Metastasis 1Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 581Carboplatin 528Cisplatin 359Bevacizumab 256pembrolizumab 228Gemcitabine 157liposomal doxorubicin 132Topotecan 131olaparib 129Cyclophosphamide 128Radiotherapy 118Taxes 114Docetaxel 95Brachytherapy 94Drug Therapy 91niraparib 88Doxorubicin 86Surveys and Questionnaires 85Magnetic Resonance Spectroscopy 80Blood Specimen Collection 74Nivolumab 71Specimen Handling 70Hyperthermic Intraperitoneal Chemotherapy 64Biopsy 63fludarabine 57Filgrastim 53Letrozole 50Oxaliplatin 49durvalumab 47Immunoglobulin G 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Panitumumab × Gynecologic × Clear all
NCT05564377 2026-06-02

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
2,900 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT01296035 2015-08-25

PanGem

Women and Infants Hospital of Rhode Island

Phase 2 Terminated
8 enrolled 6 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01388621 2013-08-20

PROVE

WiSP Wissenschaftlicher Service Pharma GmbH

Phase 2 Unknown
140 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

NCT00861120 2012-10-26

PaLiDo

Vejle Hospital

Phase 2 Completed
33 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT01158248 2010-07-09

Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
50 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡